

Children, elderly and black people preyed on by vaccine companies for first H1N1 "clinical" trials in Rochester, New York

By Global Research

Global Research, July 21, 2009

birdflu666.wordpress.com 21 July 2009

Region: **USA**

Theme: Science and Medicine

In-depth Report: THE H1N1 SWINE FLU

PANDEMIC

The H1N1 vaccine is going to be tested at the beginning of August in Rochester, New York, on those people who belong to sections of the community that have been hit especially hard by the economic downturn. The clinic conducting the trials has asked, specifically for elderly people, black people or children. In return for participating, people will get \$50-\$100 or the children will get a toy.

Novartis appears to have paid people in Poland 3 Euros to get them to participate in clinical trials of their lethal bird flu drug last summer, which caused death and injury to hundreds of people.

While the doctors and nurses have been put on trial in Poland for their role in this crime, even though it appears they were not properly informed by Novarits of the contents of the "trial" drug, Novartis has not yet had to face legal action.

Dr. Matthew Davis, the principal investigator of the Rochester trial, said that because the vaccine only uses pieces of the actual virus, there's no chance volunteer will get infected with the potentially deadly virus, according to a local newspaper.

So, here we have a doctor admitting that putting whole live attenuated viruses into the "swine flu" H1N1 jab, as Baxter, Novartis and other vaccine companies intend to do, and as WHO has instructed, could lead to an infection with a potentially deadly virus!

Infection is all the more likely if toxic adjuvants are added: even Baxter scientists state in their own clinical trials that the impact of adjuvants are negative.

"It's really as safe, actually if not safer, than the seasonal influenza vaccine that people will get every year," Davis said.

I advise those people entering this Rochester trial consult a lawyer or else to contact me jmburgermeister@gmail.com.

(Rochester, N.Y. Clinical trials for a swine flu vaccine will begin in just a few weeks in Rochester. "We run trials for the pharmaceuticals industry," said Dr. Matthew Davis.

Rochester Clinical Research is the place where vaccines earn their stripes — passing test

after test before being passed on to the public.

RCR's Associate Medical Director Dr. Davis said, "Every year, we do vaccine trials for the regular seasonal influenza. We've done a lot of the bird flu trial — the H5N1 — that everyone was concerned about, and then the swine flu virus sort of popped up unexpectedly in Mexico and... spread very rapidly."

So rapidly in fact, that companies are scrambling to find some way to block it. They need some volunteers to help.

"Anything that has ever been developed medically has been tested on human volunteers and we never have enough," Davis said. "We need to reach out to the pediatric community for this study, but minorities are often under-represented in pharmaceutical industry testing as a whole, and in this particular study as well, we need volunteers over the age of 65."

Dr. Davis is the principal investigator of the trial, and he says because the vaccine only uses pieces of the actual virus, there's no chance volunteer will get infected with the potentially deadly virus.

"It's really as safe, actually if not safer, than the seasonal influenza vaccine that people will get every year," Davis said.

Clinical trials on a swine flu vaccine begin in Rochester in August.

Besides being vaccinated against swine flu, volunteers get \$50 to \$100 per visit; four to five visits are necessary. Children are needed for this study.

For more on the study, call Rochester Clinical Research at (585) 288-0890

The original source of this article is birdflu666.wordpress.com, 2009

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Global Research

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca